Larimar Therapeutics Advances Nomlabofusp Clinical Trials for Friedreich's Ataxia
• Larimar Therapeutics is progressing with clinical trials of nomlabofusp, targeting adolescent patients with Friedreich's ataxia, with potential data expected in mid-2025.
• The FDA's acceptance of dose escalation in pediatric patients suggests confidence in nomlabofusp's safety profile, supporting a BLA submission planned for the second half of 2025.
• Analysts maintain a positive outlook on Larimar, citing the potential of nomlabofusp to address the root cause of Friedreich's ataxia and fill a market gap, especially for younger patients.
• Larimar's strong cash position is expected to fund operations into 2026, supporting the ongoing clinical development and regulatory processes for nomlabofusp.
© Copyright 2025. All Rights Reserved by MedPath